EP1175236A1 - Stent mit antimikrobiellem mittel - Google Patents

Stent mit antimikrobiellem mittel

Info

Publication number
EP1175236A1
EP1175236A1 EP00931951A EP00931951A EP1175236A1 EP 1175236 A1 EP1175236 A1 EP 1175236A1 EP 00931951 A EP00931951 A EP 00931951A EP 00931951 A EP00931951 A EP 00931951A EP 1175236 A1 EP1175236 A1 EP 1175236A1
Authority
EP
European Patent Office
Prior art keywords
stent
agent
antimicrobial
metal
zeolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00931951A
Other languages
English (en)
French (fr)
Inventor
John E. Barry
Jeffrey A. Trogolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AgION Technologies Inc
Original Assignee
AgION Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AgION Technologies LLC filed Critical AgION Technologies LLC
Publication of EP1175236A1 publication Critical patent/EP1175236A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/082—Inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/082—Inorganic materials
    • A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127

Definitions

  • the invention relates to a medical stent having antimicrobial properties.
  • Stents are devices widely used in the medical field.
  • coronary and peripheral artery stents made of metal, such as stainless steel, NiTi or tungsten. Typical of these are of the type shown in U.S. patent 5,690,670.
  • These stents also can be of metal coated with a polymer, such as polyurethane, or coated with a material such as silicone rubber. Typical of these are stents shown in U.S. Patent 5,71 3,949. Biliary, + esophageal, urinary and urethral stents often are of polymeric material.
  • Stents of a polymer material are shown in U.S. Patents 5,71 3,949 and 5,607,467.
  • stents are subject to contact with body fluids, such as blood, and with body tissue, such as arterial vessels.
  • body fluids such as blood
  • body tissue such as arterial vessels.
  • the materials contacting the stent are potential sources of contamination by bacteria.
  • the stent itself is a potential site for bacteria growth. Therefore, it would be desirable to provide the stent with antimicrobial properties. That is, it would be desirable that bacteria in the body fluids and tissue contacting the stent are killed.
  • Providing the antimicrobial properties preferably should be done in a manner which does not increase build-up of solid materials deposited on the stent and, more preferably, should reduce such build-up. Also, providing the stent with antimicrobial properties should not adversely affect the stent deployment characteristics or its mechanical properties.
  • U.S. Patent 5,906,466 describes an antimicrobial composition comprising antimicrobial silver compounds deposited on a physiologically inert oxide support material.
  • Japanese patent abstract No. 08041 61 1 an alloy exhibiting antimicrobial properties is disclosed.
  • the present invention relates to a medical stent having antimicrobial properties.
  • a coating of a material with the antimicrobial agent is applied to the stent.
  • the coating is of an adhesive type material, such as a hydrophilic polyurethane, which contains the antimicrobial agent.
  • the agent is applied to the metal stent as a powder coating. The coating can be applied to either both of the stent inner and outer surfaces.
  • the agent can be blended into the polymeric resin that forms the stent.
  • antimicrobial agent is present on both the stent inner and outer surfaces.
  • a stent of resin material can have a coating containing the agent applied to one or both of its inner and outer surfaces.
  • the antimicrobial agent is of inorganic material, preferably a zeolite.
  • a further object is a medical stent containing a zeolite as an antimicrobial agent.
  • Still an additional object is to provide a medical stent made of resin containing an inorganic antimicrobial agent.
  • Yet another object is to provide a medical stent having a coating containing an inorganic antimicrobial agent.
  • Fig. 1 is a view of a typical medical stent of metal; and Figs. 2 and 3 respectively show a plan view of a blank of material for a stent and a stent made from the blank.
  • Fig .1 shows a metal stent of the type disclosed in U.S. Patent 5,690,670. This is illustrative of any type of metal stent with which the present invention can be utilized.
  • the stent 1 60 of Fig. 1 is of the expandable type and is shown in a non-expanded state positioned on the distal end of a balloon expandable segment 1 62 of a guide wire 1 64.
  • the stent 1 60 is fabricated from a suitable material such as stainless steel, NiTi, tungsten, Ti-Nb-Zr alloy or any other suitable material.
  • the stent illustrated is designed so that it can be collapsed over a balloon segment of a balloon catheter.
  • the stent is positioned within a segment of a tubular body conduit 1 65, a blood vessel for example, to be propped open. Expansion of the balloon 1 62 expands the stent 1 60 radially outward up to the blood vessel wall 1 66 so that means for gripping soft tissue, such as barbs (not shown), on the outer surface of the stent 1 60, engage and grip blood vessel tissue to anchor the stent 1 60 in position. The balloon 1 62 is then collapsed and removed leaving the stent. In this way, the blood vessel is permanently propped open. As seen, the stent is in a position where it is contacted both by blood and body tissue.
  • one or both of the stent inner and outer surfaces has a coating 200 of a material containing an antimicrobial agent, which is described in detail below. It is preferred that at least the outer surface be coated with the material containing the agent since this comes into contact with the body tissue. The process for coating and the material are described below.
  • the metal stent described in Fig. 1 for a blood vessel is only illustrative of the type of stent with which the subject invention can be employed. It is also applicable to urinary, gastrointestinal, and other stent applications.
  • the stent can be of any shape, size and metal suitable for the application.
  • Figs. 2 and 3 show a stent of the type disclosed in U.S. Patent 5,71 3,949.
  • the stent starts as a flat piece of material 1 that has a top edge 2, a bottom edge 3 and ends 4 and 5.
  • the piece 1 includes rows of slots 6, 7 which are offset from each other.
  • the material of piece 1 is a resin, such a polyethylene, polyurethane, polytetrafluoethylene, silicone, block co-polymers of polyurethane and other suitable resins. These materials can be molded in a suitable die to produce the desired shape and slots 6, 7.
  • the piece 1 is formed into a cylindrical stent with the edges 2, 3 attached together by any suitable means such as, for example, by surface fusing, ultrasonic welding or any other suitable technique.
  • the material for piece 1 can be of metal.
  • the slots 6, 7 can be formed by laser etching or other suitable technique.
  • the agent can be incorporated directly into the resin used to make the stent.
  • a coating containing the agent also can be applied to one or both of its surfaces.
  • the inorganic antimicrobial agent preferably is applied as a coating.
  • a coating with the agent also can be applied to a stent of polymeric material, such as of Figs. 2 and 3. In either case, the coating must be adherent and flexible, the latter to accommodate flexing, bending and compression of the stent.
  • Typical thickness for the coatings are from between about 1 - 1 5 microns, preferably, between about 1 - 1 0 microns and most preferably between about 1 - 5 microns.
  • Coatings of a polymer containing the agent are preferred for both the metal and polymeric stents. These can be bonded to the stent, that is, the coating is effectively adhesively bonded to the stent.
  • the polymers for the coating can be of silicone rubber and hydrophilic polymers.
  • a preferred coating can be of, for example, a hydrophilic polymer such as hydrophilic polyurethane or a hydrophilic polymer material having a lubricious property, such as shown in U.S. Patent 5,731 ,087.
  • the antimicrobial agent preferably comprises zeolite ceramic particles mixed with the coating material. That is, the zeolite particles are blended in the desired amount into the coating material.
  • the agent particles comprise by weight of the coating between about 0.1 % - 1 00% , more preferably between about 0.1 % - 75% and most preferably between about 0.5%-50.0%.
  • the size of the particles of the agent is preferably about 1 .0 micron in nominal diameter.
  • the coating with the agent is applied by any suitable technique, such as spraying, painting or dipping the metal or resin stent into the coating material. This can be done either while the material piece forming the stent is flat or after it has its cylindrical shape. By using painting or spraying the coating with the agent can be applied to only one of the stent inner or outer surfaces. Heat and/or pressure is applied and roughening or etching of the surface is performed as needed depending upon the stent and coating materials.
  • resin for stent any suitable resin such as polyurethane, polyvinylchloride
  • agent particles 1 .0 microns
  • NiTi stainless steel
  • Ti-Nb-Zn titanium
  • tungsten tantalum
  • Metal stent with resin coating containing antimicrobial agent Metal stent with resin coating containing antimicrobial agent:
  • NiTi stainless steel
  • TiNb-Zn titanium
  • tungsten tantalum
  • Metal stents 2 and 3 above involve coating the metal with the polymer leaving the spaces 6, 7 of Figs. 2 and 3 between the metal struts free.
  • metal stent 3 above is a metal stent that is completely covered by a polymer containing the zeolite.
  • a powder coating process also can be used to apply the coating containing the antimicrobial agent.
  • a powder coating process usually comprises the basic steps of cleaning the metal, electrostatically spraying the powder onto the metal, and baking.
  • One or both of the stent surfaces can be powder coated.
  • particles of the inorganic antimicrobial, such as the ceramic particles can be incorporated into the powder, blended directly with the powder or applied in a second step to the surface of a powder coated part before the baking step.
  • Incorporation of the inorganic antimicrobial agent into the powder to be sprayed can be accomplished in any suitable way. For example, it can be done by preparing a master batch concentrate of the resin particles containing the agent particles.
  • the zeolite ceramic particles are also made in a base resin, such as polyethylene, polyurethane, etc. These resin particles containing the zeolite ceramic, are then blended into the polymer or coating material, such as by kneading or rolling to form pellets having the agent in a desired concentration. This preferably is between 0.1 to 30% by weight, preferably 0.5 to 1 5%, and most preferably 1 to 1 0% of the pellets.
  • the size of the resin containing zeolite particles in the pellets preferably is about 1 .0 micron.
  • the pellets are then ground or melt atomized to produce a powder that is used directly in the spray powder coating process. Also, the mixture can be diluted with untreated powder normally used in the conventional powder coating process.
  • An illustration of a metal stent that is powder coated follows. Metal stent that is powder coated:
  • NiTi stainless steel
  • Ti-Nb-Zn titanium
  • tungsten tantalum
  • wt% of zeolite in powder 0.1 to 1 00.0, more preferably 0.5 to
  • An alternate method is to combine untreated polymer powder with a solution of an appropriate solvent, with or without a binder, and particles of the inorganic antimicrobial to coat the polymer powder particles with the inorganic antimicrobial agent particle.
  • the solvent is then evaporated and the resulting powder composite is used in the conventional powder coating process ensuring that the inorganic antimicrobial is exposed at the surface.
  • the particle size of the ceramic resin particles of the agent also preferably is about 1 .0 micron nominal diameter.
  • Another method of producing an antimicrobial powder coating is to apply a polymer powder in the conventional manner to the stent surface or surfaces and then apply particles of the inorganic antimicrobial agent in a solvent or water.
  • the stent is then dried and, as in the conventional powder coating process, the inorganic antimicrobial agent is incorporated onto the surface of the coating.
  • the size of the particles of the agent is preferably from about 0.8 to 2.0 microns nominal diameter.
  • the inorganic antimicrobial agent is present on one or both of the stent surface to perform the intended function of killing bacteria.
  • the stent can be of a polymeric material that is prepared from a suitable resin mixture containing the agent.
  • the agent is automatically available on both surfaces of the stent.
  • These resins with the agent can be prepared by first preparing a master batch concentrate of the antimicrobial agent. That is, particles of the ceramic zeolite in the resin base are blended with a polymeric resin, such as by kneading or molding. This master batch material is formed into pellets, which can be ground to any desired size. Methods for incorporating the antibiotic agent in the resin are described in U.S. Patents Nos. 4,938,955 and 4,906,464. Final formation of the stents from the resin incorporating the antimicrobial agent can be by compression molding or other conventional forming methods.
  • the pellets of the master batch material is then added to untreated resin that is to be used to make the stent.
  • the composite of the master batch and untreated resin preferably results in a final concentration by weight of between 0.1 to 30%, preferably 0.5 to 1 5%, most preferably 1 to 1 0% of the agent zeolite particles.
  • An example of a polymeric stent follows.
  • the polyurethane is in liquid form.
  • the zeolite particles preferably in a base polyurethane resin form but also in the normal ceramic particle state, can be added to untreated polyurethane liquid to make a master batch concentrate, which is then added to untreated polyurethane to make the resin to be formed into the stent.
  • the zeolite particles in resin form or as the ceramic particles can be added directly into untreated polyurethane.
  • the liquid polyurethane with the particles of the agent are then molded to make the stent.
  • the stent has the agent throughout its entire body and on both surfaces.
  • the antibiotic particles are preferably present in a concentration by weight in the resin used to make the stent of from 0.01 to 1 0.0wt%, more preferably from 0.01 to 8.0 wt%, and most preferably from 0.1 to 5.0 wt% . They are present on the surfaces of the stent contacted by the body fluid or body tissue.
  • agent silver zeolite preferably
  • While specific amounts of the antimicrobial agent are given for the various types of stents, it should be considered that in each case that there is an amount of the agent that is sufficient to produce an effective concentration. This means that there is a sufficient amount of the antimicrobial agent used alone, added to or combined with other materials such as to prevent or inhibit the growth of bacterial and/or fungal organisms or to kill such organisms in the particular stent application.
  • the amount of the agent will vary based on the specific agent used and the material with which it is mixed or added to and upon known factors such as type and use of the stent. Environmental factors such as body temperature also should be taken into consideration. It is within the ability of one skilled in the art to relatively easily determine an effective amount of the antimicrobial agent to be used with each material.
  • the inorganic antimicrobial agent incorporated in the resin for the stent into the liquid coating material or used in the coating powder, a number of metal ions, which are inorganic materials, have been shown to possess antibiotic activity, including silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium and thallium ions. These antibiotic metal ions are believed to exert their effects by disrupting respiration and electron transport systems upon absorption into bacterial or fungal cells.
  • Antimicrobial metal ions (cations) of silver, gold, copper and zinc, in particular, are considered safe even for in vivo use. Antimicrobial silver cations are particularly useful for in vivo use due to the fact that they are not substantially absorbed into the body.
  • the inorganic antibiotic metal containing composition is an antibiotic metal salt.
  • antibiotic metal salts include silver acetate, silver benzoate, silver carbonate, silver ionate, silver iodide, silver lactate, silver laureate, silver nitrate, silver oxide, silver palpitate, silver protein, and silver sulfadiazine. Silver nitrate is preferred. These salts are particularly quick acting, as no release from ceramic particles is necessary to function antimicrobially.
  • Antibiotic ceramic particles useful with the present invention include zeolites, hydroxy apatite, zirconium phosphates or other ion-exchange ceramics. Zeolites are preferred, and are described in the preferred embodiments referred to below. Hydroxy apatite particles containing antimicrobial metals are described, e.g., in U.S. Patent No. 5,009,898. Zirconium phosphates containing antimicrobial metals are described, e.g., in U.S. Patent Nos. 5,296,238; 5,441 ,71 7; and 5,405,644.
  • Inorganic particles such as the oxides of titanium, aluminum, zinc and copper, may be coated with a composition which confers antimicrobial properties, for example, by releasing antimicrobial metal ions such as silver ions, which are described, e.g., in U.S. Patent No. 5, 1 80,585.
  • Inorganic soluble glass particles containing antimicrobial metal ions, such as silver, are described, e.g., in U.S. Patent Nos. 5,766,61 1 and 5,290,544.
  • Antibiotic zeolites are preferred. These have been prepared by replacing all or part of the ion-exchangeable ions in zeolite with ammonium ions and antibiotic metal ions, as described in U.S. Patent Nos.
  • Such zeolites have been incorporated in antibiotic resins (as shown in U.S. Patent Nos. 4,938,955 and 4,906,464) and polymer articles (U.S. Patent No. 4,775,585) .
  • Polymers including the antibiotic zeolites have been used to make refrigerators, dish washers, rice cookers, plastic film, chopping boards, vacuum bottles, plastic pails, and garbage containers.
  • Other materials in which antibiotic zeolites have been incorporated include flooring, wall paper, cloth, paint, napkins, plastic automobile parts, catheters, bicycles, pens, toys, sand, and concrete.
  • Antibiotic zeolites are well-known and can be prepared for use in the present invention using known methods. These include the antibiotic zeolites disclosed, for example, in U.S. Patent Nos. 4,938,958 and 4,91 1 ,898.
  • Zeolite is an aluminosilicate having a three dimensional skeletal structure that is represented by the formula: XM 2/n O-AI 2 O 3 -YSiO 2 -ZH 2 O.
  • M represents an ion-exchangeable ion, generally a monovalent or divalent metal ion
  • n represents the atomic valency of the (metal) ion
  • X and Y represent coefficients of metal oxide and silica respectively
  • Z represents the number of waters of crystallization.
  • zeolites examples include A-type zeolites, X-type zeolites, Y-type zeolites, T-type zeolites, high-silica zeolites, sodalite, mordenite, analcite, clinoptilolite, chabazite and erionite.
  • the present invention is not restricted to use of these specific zeolites.
  • These ion-exchange capacities are sufficient for the zeolites to undergo ion-exchange with ammonium and antibiotic metal ions.
  • the specific surface area of preferred zeolite particles is preferably at least 1 50 m 2 /g (anhydrous zeolite as standard) and the
  • SiO 2 /AI 2 O 3 mol ratio in the zeolite composition is preferably less than 1 4, more preferably less than 1 1 .
  • the antibiotic metal ions (cations) used in the antibiotic zeolites should be retained on the zeolite particles through an ion-exchange reaction.
  • Antibiotic metal ions which are adsorbed or attached without an ion-exchange reaction exhibit a decreased bactericidal effect and their antibiotic effect is not long-lasting. Nevertheless, it is advantageous for imparting quick antimicrobial action to maintain a sufficient amount of surface adsorbed metal ion.
  • the antibiotic metal ions tend to be converted into their oxides, hydroxides, basic salts etc. either in the micropores or on the surfaces of the zeolite and also tend to deposit there, particularly when the concentration of metal ions in the vicinity of the zeolite surface is high. Such deposition tends to adversely affect the bactericidal properties of ion-exchanged zeolite.
  • a relatively low degree of ion exchange is employed to obtain superior bactericidal properties. It is believed to be required that at least a portion of the zeolite particles retain metal ions having bactericidal properties at ion-exchangeable sites of the zeolite in an amount less than the ion-exchange saturation capacity of the zeolite. In one embodiment, the zeolite employed in the present invention retains antimicrobial metal ions in an amount up to 41 % of the theoretical ion-exchange capacity of the zeolite. Such ion-exchanged zeolite with a relatively low degree of ion-exchange may be prepared by performing ion-exchange using a metal ion solution having a low concentration as compared with solutions conventionally used for ion exchange.
  • the antibiotic metal ion is preferably present in the range of from about 0.1 to 20.0 wt. % of the zeolite.
  • the zeolite contains from 0.1 to 20.0 wt. % of silver ions and from 0.1 to 20.0 wt. % of copper or zinc ions.
  • ammonium ion can be contained in the zeolite at a concentration of about 20.0 wt. % or less of the zeolite, it is desirable to limit the content of ammonium ions to from 0.5 to 1 5.0 wt.%, preferably 1 .5 to 5.0 wt. %.
  • a preferred antibiotic zeolite is type A zeolite containing either a combination of ion-exchanged silver, zinc, and ammonium or silver and ammonium.
  • One such zeolite is manufactured by Shinagawa, Inc. under the product number AW-1 0N and consists of 0.6% by weight of silver ion- exchanged in Type A zeolite particles having a diameter of about 2.5/;.
  • Another formulation, AJ-1 0N consists of about 2% by weight silver ion- exchanged in Type A zeolite particles having a diameter of about 2.5 ⁇ .
  • AW-80 contains 0.6% by weight of silver ion- exchanged in Type A zeolite particles having a diameter of about 1 .0 ⁇ .
  • Another formulation, AJ-80N consists of about 2% by weight silver ion- exchanged in Type A zeolite particles having a diameter of about 1 .0 ⁇ .
  • These zeolites preferably contain about between 0.5 % and 2.5% by weight of ion- exchanged ammonium.
  • Other formulations also are available.
  • the zeolites are often obtained in master batches of low density polyethylene, polypropylene, or polystyrene, containing about 20.0 wt. % of the zeolite. Thus, they can be easily mixed with the resins used as materials for forming the composite resin used to make the stent or in the liquid coating material.
  • the antibiotic properties of the antibiotic zeolite particles of the invention may be assayed while in aqueous formulations using conventional assay techniques, including for example determining the minimum growth inhibitory concentration (MIC) with respect to a variety of bacteria, eumycetes and yeast.
  • MIC minimum growth inhibitory concentration
  • the bacteria listed below may be employed: such a test, the bacteria listed below may be employed:
  • the assay for determining MIC can be carried out by smearing a solution containing bacteria for inoculation onto a plate culture medium to which a test sample of the encapsulated antibiotic zeolite particles is added in a particular concentration, followed by incubation and culturing of the plate.
  • the MIC is defined as a minimum concentration thereof required for inhibiting the growth of each bacteria.
  • the antibiotic zeolites are exceptionally suitable under relevant toxicity and biocompatibility standards for use in the stents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
EP00931951A 1999-04-23 2000-04-21 Stent mit antimikrobiellem mittel Withdrawn EP1175236A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US298545 1994-08-30
US29854599A 1999-04-23 1999-04-23
PCT/US2000/011092 WO2000064506A1 (en) 1999-04-23 2000-04-21 Stent having antimicrobial agent

Publications (1)

Publication Number Publication Date
EP1175236A1 true EP1175236A1 (de) 2002-01-30

Family

ID=23150978

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00931951A Withdrawn EP1175236A1 (de) 1999-04-23 2000-04-21 Stent mit antimikrobiellem mittel

Country Status (3)

Country Link
EP (1) EP1175236A1 (de)
AU (1) AU4975500A (de)
WO (1) WO2000064506A1 (de)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028851B2 (en) 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US6776792B1 (en) 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
US6503954B1 (en) 2000-03-31 2003-01-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing actinomycin D and a method of forming the same
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6713119B2 (en) 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
US6503556B2 (en) 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6759054B2 (en) 1999-09-03 2004-07-06 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol composition and coating
US6749626B1 (en) 2000-03-31 2004-06-15 Advanced Cardiovascular Systems, Inc. Actinomycin D for the treatment of vascular disease
US6908624B2 (en) 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6818247B1 (en) 2000-03-31 2004-11-16 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent
US6527801B1 (en) 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US6989156B2 (en) 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US20030185901A1 (en) 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US20030180379A1 (en) 2000-07-27 2003-09-25 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US6451373B1 (en) 2000-08-04 2002-09-17 Advanced Cardiovascular Systems, Inc. Method of forming a therapeutic coating onto a surface of an implantable prosthesis
US7402173B2 (en) 2000-09-18 2008-07-22 Boston Scientific Scimed, Inc. Metal stent with surface layer of noble metal oxide and method of fabrication
US7101391B2 (en) 2000-09-18 2006-09-05 Inflow Dynamics Inc. Primarily niobium stent
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6783793B1 (en) 2000-10-26 2004-08-31 Advanced Cardiovascular Systems, Inc. Selective coating of medical devices
US6833153B1 (en) 2000-10-31 2004-12-21 Advanced Cardiovascular Systems, Inc. Hemocompatible coatings on hydrophobic porous polymers
US6824559B2 (en) 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
US6540776B2 (en) 2000-12-28 2003-04-01 Advanced Cardiovascular Systems, Inc. Sheath for a prosthesis and methods of forming the same
US7504125B1 (en) 2001-04-27 2009-03-17 Advanced Cardiovascular Systems, Inc. System and method for coating implantable devices
US6663662B2 (en) 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US6780424B2 (en) 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US6712845B2 (en) 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
US7651695B2 (en) 2001-05-18 2010-01-26 Advanced Cardiovascular Systems, Inc. Medicated stents for the treatment of vascular disease
US6743462B1 (en) 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7247313B2 (en) 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US6565659B1 (en) 2001-06-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US6656216B1 (en) 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
US7285304B1 (en) 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US6863683B2 (en) 2001-09-19 2005-03-08 Abbott Laboratoris Vascular Entities Limited Cold-molding process for loading a stent onto a stent delivery system
US6753071B1 (en) 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US7223282B1 (en) 2001-09-27 2007-05-29 Advanced Cardiovascular Systems, Inc. Remote activation of an implantable device
US7585516B2 (en) 2001-11-12 2009-09-08 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
US7175874B1 (en) 2001-11-30 2007-02-13 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US7357949B2 (en) 2001-12-21 2008-04-15 Agion Technologies Inc. Encapsulated inorganic antimicrobial additive for controlled release
US6709514B1 (en) 2001-12-28 2004-03-23 Advanced Cardiovascular Systems, Inc. Rotary coating apparatus for coating implantable medical devices
US7022334B1 (en) 2002-03-20 2006-04-04 Advanced Cardiovascular Systems, Inc. Therapeutic composition and a method of coating implantable medical devices
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7005137B1 (en) 2002-06-21 2006-02-28 Advanceed Cardiovascular Systems, Inc. Coating for implantable medical devices
US7396539B1 (en) 2002-06-21 2008-07-08 Advanced Cardiovascular Systems, Inc. Stent coatings with engineered drug release rate
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7622146B2 (en) 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US7294329B1 (en) 2002-07-18 2007-11-13 Advanced Cardiovascular Systems, Inc. Poly(vinyl acetal) coatings for implantable medical devices
US7491233B1 (en) 2002-07-19 2009-02-17 Advanced Cardiovascular Systems Inc. Purified polymers for coatings of implantable medical devices
US7363074B1 (en) 2002-08-20 2008-04-22 Advanced Cardiovascular Systems, Inc. Coatings comprising self-assembled molecular structures and a method of delivering a drug using the same
US7732535B2 (en) 2002-09-05 2010-06-08 Advanced Cardiovascular Systems, Inc. Coating for controlled release of drugs from implantable medical devices
US7201935B1 (en) 2002-09-17 2007-04-10 Advanced Cardiovascular Systems, Inc. Plasma-generated coatings for medical devices and methods for fabricating thereof
US7438722B1 (en) 2002-09-20 2008-10-21 Advanced Cardiovascular Systems, Inc. Method for treatment of restenosis
US7232573B1 (en) 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US8202530B2 (en) 2002-09-27 2012-06-19 Advanced Cardiovascular Systems, Inc. Biocompatible coatings for stents
US8337937B2 (en) 2002-09-30 2012-12-25 Abbott Cardiovascular Systems Inc. Stent spin coating method
US7404979B1 (en) 2002-09-30 2008-07-29 Advanced Cardiovascular Systems Inc. Spin coating apparatus and a method for coating implantable devices
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US7022372B1 (en) 2002-11-12 2006-04-04 Advanced Cardiovascular Systems, Inc. Compositions for coating implantable medical devices
US6896965B1 (en) 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US8034361B2 (en) 2002-11-12 2011-10-11 Advanced Cardiovascular Systems, Inc. Stent coatings incorporating nanoparticles
DE10253634A1 (de) * 2002-11-13 2004-05-27 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endoprothese
US6982004B1 (en) 2002-11-26 2006-01-03 Advanced Cardiovascular Systems, Inc. Electrostatic loading of drugs on implantable medical devices
US7211150B1 (en) 2002-12-09 2007-05-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating and drying multiple stents
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7074276B1 (en) 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US8715771B2 (en) 2003-02-26 2014-05-06 Abbott Cardiovascular Systems Inc. Coated stent and method of making the same
US7563483B2 (en) 2003-02-26 2009-07-21 Advanced Cardiovascular Systems Inc. Methods for fabricating a coating for implantable medical devices
US7063884B2 (en) 2003-02-26 2006-06-20 Advanced Cardiovascular Systems, Inc. Stent coating
US7255891B1 (en) 2003-02-26 2007-08-14 Advanced Cardiovascular Systems, Inc. Method for coating implantable medical devices
US6926919B1 (en) 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
US7288609B1 (en) 2003-03-04 2007-10-30 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices based on poly (orthoesters)
US7563454B1 (en) 2003-05-01 2009-07-21 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US7323209B1 (en) 2003-05-15 2008-01-29 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating stents
AU2004241896B2 (en) * 2003-05-23 2008-11-06 Gambro Lundia Ab Biocompatible polymer
SE526027C2 (sv) 2003-05-23 2005-06-14 Gambro Lundia Ab Biokompatibel polymerkomposition, förfarande för beredning av en biokompatibel sampolymerkomposition, artikel med en film av en polymerkomposition och användning av en biokompatibel polymerkomposition för en medicinsk anordning
US7186789B2 (en) 2003-06-11 2007-03-06 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7645504B1 (en) 2003-06-26 2010-01-12 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers
WO2005003032A1 (en) 2003-07-03 2005-01-13 The University Court Of The University Of St Andrews Zeolites for delivery of nitric oxide
US7875285B1 (en) 2003-07-15 2011-01-25 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices having controlled rate of release
US7056591B1 (en) 2003-07-30 2006-06-06 Advanced Cardiovascular Systems, Inc. Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US7169404B2 (en) 2003-07-30 2007-01-30 Advanced Cardiovasular Systems, Inc. Biologically absorbable coatings for implantable devices and methods for fabricating the same
US7431959B1 (en) 2003-07-31 2008-10-07 Advanced Cardiovascular Systems Inc. Method and system for irradiation of a drug eluting implantable medical device
US7441513B1 (en) 2003-09-26 2008-10-28 Advanced Cardiovascular Systems, Inc. Plasma-generated coating apparatus for medical devices and a method of coating deposition
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7318932B2 (en) 2003-09-30 2008-01-15 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same
US7329413B1 (en) 2003-11-06 2008-02-12 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof
US7261946B2 (en) 2003-11-14 2007-08-28 Advanced Cardiovascular Systems, Inc. Block copolymers of acrylates and methacrylates with fluoroalkenes
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US7560492B1 (en) 2003-11-25 2009-07-14 Advanced Cardiovascular Systems, Inc. Polysulfone block copolymers as drug-eluting coating material
US7220816B2 (en) 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US7563324B1 (en) 2003-12-29 2009-07-21 Advanced Cardiovascular Systems Inc. System and method for coating an implantable medical device
US20050214339A1 (en) 2004-03-29 2005-09-29 Yiwen Tang Biologically degradable compositions for medical applications
US7553377B1 (en) 2004-04-27 2009-06-30 Advanced Cardiovascular Systems, Inc. Apparatus and method for electrostatic coating of an abluminal stent surface
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US7563780B1 (en) 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
EP2111881A1 (de) * 2004-07-05 2009-10-28 Ziscoat N.V. biokompatible Beschichtungen für medizinische vorrichtungen mit Molekularsieben
US7494665B1 (en) 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US7311980B1 (en) 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US9283099B2 (en) 2004-08-25 2016-03-15 Advanced Cardiovascular Systems, Inc. Stent-catheter assembly with a releasable connection for stent retention
US7244443B2 (en) 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US7229471B2 (en) 2004-09-10 2007-06-12 Advanced Cardiovascular Systems, Inc. Compositions containing fast-leaching plasticizers for improved performance of medical devices
US7166680B2 (en) 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US7481835B1 (en) 2004-10-29 2009-01-27 Advanced Cardiovascular Systems, Inc. Encapsulated covered stent
US7390497B2 (en) 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7214759B2 (en) 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US7588642B1 (en) 2004-11-29 2009-09-15 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method using a brush assembly
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
US7604818B2 (en) 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US7419504B2 (en) 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US7202325B2 (en) 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
US7381048B2 (en) 2005-04-12 2008-06-03 Advanced Cardiovascular Systems, Inc. Stents with profiles for gripping a balloon catheter and molds for fabricating stents
US7637941B1 (en) 2005-05-11 2009-12-29 Advanced Cardiovascular Systems, Inc. Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
US7291166B2 (en) 2005-05-18 2007-11-06 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
DE102005024913A1 (de) 2005-05-31 2006-12-14 Axetis Ag Gefäßstents
EP1728522B1 (de) * 2005-05-31 2013-05-22 Axetis AG Beschichtete Stents
US7622070B2 (en) 2005-06-20 2009-11-24 Advanced Cardiovascular Systems, Inc. Method of manufacturing an implantable polymeric medical device
US7297758B2 (en) 2005-08-02 2007-11-20 Advanced Cardiovascular Systems, Inc. Method for extending shelf-life of constructs of semi-crystallizable polymers
US7476245B2 (en) 2005-08-16 2009-01-13 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US9248034B2 (en) 2005-08-23 2016-02-02 Advanced Cardiovascular Systems, Inc. Controlled disintegrating implantable medical devices
US7591841B2 (en) 2005-12-16 2009-09-22 Advanced Cardiovascular Systems, Inc. Implantable devices for accelerated healing
US7638156B1 (en) 2005-12-19 2009-12-29 Advanced Cardiovascular Systems, Inc. Apparatus and method for selectively coating a medical article
US20070156230A1 (en) 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US7601383B2 (en) 2006-02-28 2009-10-13 Advanced Cardiovascular Systems, Inc. Coating construct containing poly (vinyl alcohol)
US7691400B2 (en) * 2006-05-05 2010-04-06 Medtronic Vascular, Inc. Medical device having coating with zeolite drug reservoirs
US20130331926A1 (en) 2006-05-26 2013-12-12 Abbott Cardiovascular Systems Inc. Stents With Radiopaque Markers
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8333000B2 (en) 2006-06-19 2012-12-18 Advanced Cardiovascular Systems, Inc. Methods for improving stent retention on a balloon catheter
US9072820B2 (en) 2006-06-26 2015-07-07 Advanced Cardiovascular Systems, Inc. Polymer composite stent with polymer particles
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US7757543B2 (en) 2006-07-13 2010-07-20 Advanced Cardiovascular Systems, Inc. Radio frequency identification monitoring of stents
US9173733B1 (en) 2006-08-21 2015-11-03 Abbott Cardiovascular Systems Inc. Tracheobronchial implantable medical device and methods of use
US20080119927A1 (en) * 2006-11-17 2008-05-22 Medtronic Vascular, Inc. Stent Coating Including Therapeutic Biodegradable Glass, and Method of Making
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
EP2187988B1 (de) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprothese mit nicht verschmutzender oberfläche
WO2009020520A1 (en) 2007-08-03 2009-02-12 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
FR2922773A1 (fr) * 2007-10-29 2009-05-01 Leary Patrick O Prothese chirurgicale
US8211489B2 (en) 2007-12-19 2012-07-03 Abbott Cardiovascular Systems, Inc. Methods for applying an application material to an implantable device
US8361538B2 (en) 2007-12-19 2013-01-29 Abbott Laboratories Methods for applying an application material to an implantable device
ES2423504T3 (es) 2008-04-22 2013-09-20 Boston Scientific Scimed, Inc. Dispositivos médicos que tienen un recubrimiento de material inorgánico
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US8726483B2 (en) 2011-07-29 2014-05-20 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US9700443B2 (en) 2015-06-12 2017-07-11 Abbott Cardiovascular Systems Inc. Methods for attaching a radiopaque marker to a scaffold
US11167064B2 (en) 2016-07-14 2021-11-09 Hollister Incorporated Hygienic medical devices having hydrophilic coating

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6415056A (en) * 1987-07-09 1989-01-19 Hanarou Maeda Body indwelling tube
US5477864A (en) * 1989-12-21 1995-12-26 Smith & Nephew Richards, Inc. Cardiovascular guidewire of enhanced biocompatibility
JPH0762242A (ja) * 1993-08-27 1995-03-07 Shin Etsu Chem Co Ltd 抗菌・抗かび性シリコーンゴム組成物
JPH0780080A (ja) * 1993-09-14 1995-03-28 Nissho Corp 抗菌性コネクタ
EP0781566B1 (de) * 1995-12-26 2004-07-28 Toyo Boseki Kabushiki Kaisha In organischen Lösungsmitteln lösliche Mucopolysaccharide, antibakterielles antithrombogenes Mittel und medizinisches Material
US6015816A (en) * 1996-02-29 2000-01-18 The Research Foundation Of State University Of New York Antimicrobial compositions
US6436422B1 (en) * 1998-11-23 2002-08-20 Agion Technologies L.L.C. Antibiotic hydrophilic polymer coating

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0064506A1 *

Also Published As

Publication number Publication date
AU4975500A (en) 2000-11-10
WO2000064506A1 (en) 2000-11-02
WO2000064506A9 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
EP1175236A1 (de) Stent mit antimikrobiellem mittel
US6582715B1 (en) Antimicrobial orthopedic implants
EP1133327B1 (de) Antibiotische hydrophile beschichtung
US6267590B1 (en) Antimicrobial dental products
US6866859B2 (en) Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties
US6123925A (en) Antibiotic toothpaste
AU616472B2 (en) Infection-resistant compositions, medical devices and surfaces and method for preparing and using same
US6645483B2 (en) Lubricious coating
CN100563440C (zh) 抗微生物复合材料
CA2639838C (en) Antimicrobial lubricious coating
WO2000032247A9 (en) Antimicrobial fabric and medical graft of the fabric
EP0251783A2 (de) Antimikrobielle Zusammensetzung
US20020012760A1 (en) Antimicrobial food tray
EP1044139A1 (de) Antimikrobielle kunststoffverschlüsse für trinkgefässe
WO2001034686A2 (en) Flexible foam products incorporating an inorganic antimicrobial agent and methods of manufacture
WO2014138885A1 (en) Polymeric coatings having antimicrobial properties
AU2002246277B2 (en) Lubricious coating comprising pharmacological additives
AU2002246277A1 (en) Lubricious coating comprising pharmacological additives
WO2000064259A1 (en) Cooler chest with antimicrobial properties
WO2001037670A2 (en) Antimicrobial hook and loop fastener
WO2000014284A1 (en) Antimicrobial footwear and process of manufacture
HK1059056B (en) Lubricious coating comprising pharmacological additives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGION TECHNOLOGIES, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081031